Aspiro Pharma

Aspiro Pharma specializes in the research, development, and manufacturing of generic parenteral formulations—primarily powder, lyophilized, and liquid injectables. The company has a modern facility near Hyderabad conforming to global regulatory standards. It exports primarily to the US market (~75–80% of revenue), with a focus on anti-emetic and anti-convulsant products making up most sales. The company began commercial operations in mid-FY22 after initial contract manufacturing work during COVID‑19. Financial performance has been negative due to high costs at early scale but expected to improve as production ramps up with new product approvals anticipated from FY25 onward.